RhumbLine Advisers
KRON

RhumbLine Advisers’s Kronos Bio KRON Stock Holding History

RhumbLine Advisers’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,088
Closed -$2.59K – 4268
2024
Q2 		$2.59K Hold
2,088
– – ﹤0.01% 4163
2024
Q1 		$2.71K Hold
2,088
– – ﹤0.01% 4057
2023
Q4 		$2.61K Hold
2,088
– – ﹤0.01% 4068
2023
Q3 		$2.71K Sell
2,088
-4,168
-67% -$6.73K ﹤0.01% 4078
2023
Q2 		$10.8K Sell
6,256
-55,903
-90% -$88.8K ﹤0.01% 3931
2023
Q1 		$91K Buy
62,159
+849
+1% +$1.63K ﹤0.01% 2864
2022
Q4 		$99K Buy
61,310
+81
+0.1% +$186 ﹤0.01% 2905
2022
Q3 		$205K Buy
61,229
+4,974
+9% +$22.5K ﹤0.01% 2887
2022
Q2 		$205K Buy
56,255
+7,527
+15% +$34.1K ﹤0.01% 2919
2022
Q1 		$352K Sell
48,728
-2,657
-5% -$22.7K ﹤0.01% 2584
2021
Q4 		$698K Sell
51,385
-604
-1% -$9.45K ﹤0.01% 2364
2021
Q3 		$1.09M Buy
51,989
+1,743
+3% +$37.4K ﹤0.01% 2190
2021
Q2 		$1.2M Buy
50,246
+35,056
+231% +$887K ﹤0.01% 2161
2021
Q1 		$445K Buy
15,190
+2,034
+15% +$59.6K ﹤0.01% 2542
2020
Q4 		$393K Buy
+13,156
New +$413K ﹤0.01% 2542

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RhumbLine Advisers's KRON Position: Q3 2024 in Review

RhumbLine Advisers sold out of Kronos Bio (KRON) in Q3 2024, closing a stake of 2,088 shares — an estimated $2.59K sold.

RhumbLine Advisers first reported a position in KRON in Q4 2020 and held it in 15 quarters. The position peaked at $1.2M in Q2 2021. 53 funds tracked by Wall St. Rank hold KRON as of Q3 2024.

  • RhumbLine Advisers reported no remaining Kronos Bio position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 2,088 Kronos Bio shares in Q3 2024, an estimated $2.59K.
  • RhumbLine Advisers first reported a position in Kronos Bio in Q4 2020 and held it in 15 quarters.
  • RhumbLine Advisers's Kronos Bio position peaked at $1.2M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.